Pitch for Investment

Latest Insights, Interviews, News, and Resources.

The latest news from UKI2S and our portfolio companies

Cobalt Light Systems

UK Innovation & Science Seed Fund Portfolio Company, Cobalt Light Systems, Acquired by Agilent for £40m

7th July 2017

Chemical detection innovator secures access to global markets.
Ideas

Thinking about the upside for the UK in innovation

6th July 2017

As you may have read in our Chairman Ian Taylor’s recent blog “For the Love of Spinouts,” you’ll know that UKI2S hosted an event with the Innovate UK Catapult network…
Steps

Update: New investments & significant advancements

8th June 2017

UKI2S portfolio update:  New investments in Linear Diagnostics & Nemesis Bioscience + significant advancements for Quethera & Cytox
Spin-out science funding

For the Love of Spin Outs

25th May 2017

With the increasing presence in our lives of robotics, artificial intelligence, genomics and a host of new technologies changing the way we fight diseases…
Lab work

Neuroprotective Therapy Company Quethera Reveals Gene Therapy Results at ARVO

23rd May 2017

Quethera, a biopharmaceutical company developing therapies for ocular disorders, today presented strong efficacy data at the 2017 Association for Research in Vision and Ophthalmology (ARVO)…
Nemesis Bioscience

Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes

8th May 2017

Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000…

Cytox Plans US Clinical Launch for Early-Stage Alzheimer’s Test While Courting Pharma Partners

4th May 2017

British molecular diagnostics company Cytox plans to make a molecular test for the early-stage diagnosis of Alzheimer’s disease available in the US by year end.
Money

UKI2S & Innovate UK partner to fund infrastructure systems and health and life sciences growth companies

19th April 2017

UK Innovation & Science Seed Fund is partnering with Innovate UK’s £8.5 million Investment Accelerator pilot to fund innovative high-risk projects and invest in companies that have real potential for growth in…
Medication

UK Innovation & Science Seed Fund & University of Birmingham Back Promising Technology Spinout Linear Diagnostics

24th March 2017

Spinout developing novel hand-held reader to help in the fight against antibiotic resistance.
Illustration

CRISPR-Cas9 helps blind rats to see

25th January 2017

Researchers looking into retinitis pigmentosa have been able to improve vision in rats using the CRISPR-Cas9 gene editing technology.
Sunscreen crops

Cutting down on the sunscreen could mean heavier crops

16th January 2017

Plants get damaged by the sun just like people, and they protect themselves from sun damage by a process known as photoprotection…
Speaking at event

Oliver Sexton Joins Investor Panels at IBioIC & Biotech & Money 2017 Conferences

9th January 2017

UKI2S Investment Manager Oliver Sexton will chair the Innovation Investment panel to provide an insight into the opportunities available for startups.
national cancer institute

China has pipped the US to the post for CRISPR-Cas9 clinical trials

6th December 2016

Scientists in China have become the first in the world to administer CRISPR-Cas9-edited cells to humans.

Circuits

UK Innovation & Science Seed Fund’s £200m Investment in UK’s “Deep Science”

28th November 2016

Early-stage venture fund key in bridging gap between UK research and commercialisation. Fund aims to turn UK scientific ‘world’s first’…
Biofuel

Alaska airlines flies on synthbio jet fuel

17th November 2016

Alaska Airlines and the Washington State University-led Northwest Advanced Renewables Alliance (NARA) made history on 14 November 2016 by flying…
national cancer institute

CellCentric wins Innovate UK award to expand use of p300/CBP inhibitors in cancer

9th November 2016

CellCentric is developing first in class drug compounds against a key regulator of cancer.

Tokamak Energy

Tokamak Energy & Synthace named World Economic Forum Technology Pioneers

7th November 2016

Two UKI2S portfolio companies recognised amongst world’s most innovative companies.
Crescendo

Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m

10th October 2016

Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics.
Sir Richard Sykes

Bio-start Confirms Sir Richard Sykes as Chair of Judging Panel

10th October 2016

SynbiCITE and UK Innovation & Science Seed Fund today announce that Sir Richard Sykes, Chairman of the Royal Institution of Great Britain, Chairman of…
Mark White

A Discussion with Mark White Investment Director UK Innovation & Science Seed Fund

1st October 2016

Mark White, BA, MBA, is Midven’s investment director and is an investment committee member of the UK Innovation & Science Seed Fund.
Microphone

Oliver Sexton Speaking at Innovation in Engineering Biology (11 October)

29th September 2016

On 11 October in London, UK Innovation & Science Seed Fund Investment Director Oliver Sexton will be speaking at the Innovation Forum’s Innovation in Engineering Biology conference. The event joins leading engineering biology experts from academia and industry with entrepreneurs, investors and policymakers to review the current environment and explore future trends in the field….

Device

UK Innovation & Science Seed Fund Invests in AgPlus Diagnostics

28th September 2016

AgPlus’ handheld electrochemical reader to deliver the next generation of rapid diagnostics.
Announce

SynbiCITE and UK Innovation & Science Seed Fund announce judge for Bio-start competition

27th September 2016

Sciad Newswire / SynbiCITE and UK Innovation & Science Seed Fund today announce that Dr David Lawrence, Non-executive…
Andrew Muir

A Discussion with Dr Andrew Muir Midven Director

23rd September 2016

Andrew Muir, PhD, is a director at Midven, and leads the UK Innovation & Science Seed Fund team.
UKI2S

© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, t/a Midven, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.

Stay updated